Skip to main content
RaQualia Pharma Inc. logo

RaQualia Pharma Inc. — Investor Relations & Filings

Ticker · 4579 ISIN · JP3967150008 T Professional, scientific and technical activities
Open in API
Filings indexed 89 across all filing types
Latest filing 2023-03-27 Governance Information
Country JP Japan
Listing T 4579

About RaQualia Pharma Inc.

https://www.raqualia.com/en/index.html

RaQualia Pharma Inc. is a research and development-focused pharmaceutical company that specializes in the discovery and development of innovative small molecule compounds. The company's primary activities involve conducting exploratory research to identify novel drug candidates and advancing them through preclinical and clinical studies. Its business model centers on creating value by out-licensing the intellectual property of these compounds to other pharmaceutical companies for final development and commercialization. A key product originating from its research is tegoprazan (K-CAB®), a potassium-competitive acid blocker used for treating gastroesophageal reflux disease and other acid-related conditions.

Recent filings

Filing Released Lang Actions
内部統制報告書－第15期(2022/01/01－2022/12/31)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法) in Japan. This type of report is a mandatory regulatory filing concerning the effectiveness of internal controls over financial reporting. Since it is a specific regulatory requirement that does not fit into categories like 10-K (Annual Report) or IR (Interim Report), and is not merely an announcement of a report, it falls under the 'Regulatory Filings' category.
2023-03-27 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, which accompanies the Annual Securities Report (Yuuka Shouken Houkokusho) in Japan. It confirms the accuracy of the financial statements for the 15th fiscal period. Since it is a regulatory filing required by law to accompany the annual report and does not fit into the specific categories like 10-K (which is the report itself) or other specialized categories, it is classified as a Regulatory Filing (RNS). FY 2022
2023-03-27 Japanese
有価証券報告書－第15期(2022/01/01－2022/12/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, management discussion, and corporate information for the fiscal year ending December 31, 2022. It is not an announcement or a summary, but the full statutory filing submitted to the Tokai Local Finance Bureau. FY 2022
2023-03-27 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of the 3rd Quarter Report (第３四半期報告書). Since it is a formal regulatory filing confirming the validity of a quarterly report rather than the quarterly report itself, and it does not fit into specific categories like earnings releases or management reports, it is classified as a general regulatory filing.
2022-11-11 Japanese
四半期報告書－第15期第3四半期(令和4年7月1日－令和4年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for RaQualia Pharma Inc. covering the third quarter of the 15th fiscal period (July 1, 2022, to September 30, 2022). It contains detailed financial statements, including the balance sheet, income statement, and cash flow statement, as well as management's analysis of financial conditions. This fits the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-11 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly states it is a certification regarding the accuracy of the quarterly report (第２四半期報告書) under the Financial Instruments and Exchange Act. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report, should be classified as Regulatory Filings (RNS) rather than the report itself. Q2 2022
2022-08-15 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.